Tomorrow, 5:00 PM CEST. 🔴
New evidence, expert perspectives, clinical insights > first-line BRAF mCRC care, live with MD Anderson and Poitiers. Last chance to register (free, and you'll get the replay):
@juisci.bsky.social
@juisci.bsky.socialTomorrow, 5:00 PM CEST. 🔴
New evidence, expert perspectives, clinical insights > first-line BRAF mCRC care, live with MD Anderson and Poitiers. Last chance to register (free, and you'll get the replay):
@juisci.bsky.socialRegistration takes 30 seconds, registrants get the replay.
@juisci.bsky.socialWe put all of it in a 16-page read: what BREAKWATER establishes, what it doesn't, and where the uncertainty lands in a real clinical decision.
Free, no form:
drive.google.com/file/d/1kiJL...
@juisci.bsky.socialSeptember 22 · 5:00 PM CEST · 90 min · live Q&A · in English · free for healthcare professionals.
@sigtrans-sttt.bsky.socialCan oral anlotinib match bevacizumab in first-line #mCRC?
In the phase 3 ANCHOR trial, both CapeOX combinations achieved 11.0-month median PFS, but anlotinib missed the noninferiority margin and caused more grade ≥3 toxicity.
@tamedoncol.bsky.socialOn #TAMO in 2025.
.
In a retrospective 20-center study, a depth of response ≥15% independently predicted longer PFS in pre-treated BRAFV600E #mCRC receiving encorafenib + cetuximab ± binimetinib.
Read more:
journals.sagepub.com/doi/full/10....
@Guv_onc @ChiaraCrem1 #colorectal #cancer